Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01298349
Other study ID # 104-10
Secondary ID
Status Completed
Phase
First received
Last updated
Start date February 2011
Est. completion date December 2017

Study information

Verified date February 2020
Source HaEmek Medical Center, Israel
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The present study aimed to examine face and object perception processes in schizophrenic patients. Schizophrenia is associated with deficits in visual processing that represent a key feature in the disorder. Previous studies have shown that schizophrenics exhibit deficits in a variety of facial-processing tasks (e.g., face recognition, recognition of facial expressions), that may severely hinder the patients' interpersonal and social skills. Some investigators have attributed these deficits to impairments in configural processing in schizophrenia. That is, an impairment in the ability to process the spatial relations between the constituent parts of a configuration (e.g., the spacing between the eyes of a given face). To date, studies aimed to investigate this possibility (e.g., Schwartz et al., 2002; Yong-Wook et al., 2008) yielded conflicting results. Additionally, it is not yet clear whether the hypothesized impairment in configural processing is restricted to faces, or whether it is more general in nature and applies to objects as well.


Description:

In the present study we investigate the relative contribution of component versus configural properties to face and object perception in schizophrenic and control subjects. To this end, we designed a series of experiments that are based on former work by Kimchi and Palmer (1982), and on my Ph.D. dissertation conducted under the supervision of Prof. Ruth Kimchi at the IIPDM.

Experiment 1 investigates the relative roles of local parts versus global configuration in object perception by applying a technique formalized by Kimchi and Palmer (1982). Participants are presented with hierarchical figures, in which larger figures (e.g., a "global" triangle) are constructed by smaller figures (e.g., "local" squares).

Participants (schizophrenics and controls) perform a similarity-judgment task. In each experimental trial, participants are presented with a triad of stimuli: a standard figure and two comparison figures. Participants are asked to determine which of the two comparison figures is more similar to the standard. Each figure consists of a global square or triangle made of local squares or triangles. In the "same configuration" comparison figure different elements are arranged in the same configuration as the standard figure. In the "same element" comparison figure, the same elements as in the standard figure are used, but are arranged in a different configuration. The number of elements used to construct the standard figure is varied. Previous data with normal perceivers (Kimchi & Palmer, 1982) showed that as the number of elements increased (and their sizes decreased) perceivers tended to base their similarity judgments on the global configuration, rather than on its local elements. If schizophrenics are impaired in their ability to process configural information then their similarity judgments should mainly rely on the local elements rather than on the global configuration.

Experiment 2 examines the relative contribution of facial components (e.g., eyes, nose, mouth) versus configural properties (e.g., spacing between the eyes) to face perception, by applying Garner's speeded classification paradigm (Garner, 1974). We have previously applied this paradigm in my Ph.D. dissertation to study face perception in normal perceivers.

The stimulus set consists of four faces created by orthogonally combining components (eyes, nose, and mouth) and configural information (inter-eyes distance and nose-mouth distance). On each trial participants are asked to classify a face on either its components or its configural information, in two conditions. In the control condition only one facial dimension varies (e.g., components) while the other dimension (e.g., configural information) is held constant. In the filtering condition the two dimensions are varied orthogonally. Equal performance in the control and filtering conditions indicates that participants are able to selectively attend to the relevant dimension - the dimensions are processed independently. Poorer performance in the filtering condition than in the control condition - Garner interference - indicates that it is not possible to selectively attend to one dimension while ignoring another, irrelevant dimension - the dimensions are processed interactively.

Results with normal perceivers revealed a symmetric Garner interference with upright faces: participants were unable to selectively attend to components and ignore irrelevant variation in configural information, and vice versa. These results imply perceptual interdependence in processing components and configural information. If schizophrenics are impaired in their ability to process configural information then patients should be able to selectively attend to components and ignore irrelevant variation in configural information, but not vice versa. This pattern would indicate the relative dominance of components over configural properties in upright face processing of schizophrenia patients.


Recruitment information / eligibility

Status Completed
Enrollment 71
Est. completion date December 2017
Est. primary completion date December 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- schizophrenia or schizo-affective disorder

- normal population with no psychiatric history

- Stable medication for at least a month before participating in the study

- subjects must have normal vision or revised

Exclusion Criteria:

- deterioration of the disorder

- subject will

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Israel Haemek Medical Center Afula

Sponsors (1)

Lead Sponsor Collaborator
HaEmek Medical Center, Israel

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary Performance in Experiment 1: Probability of Global Perception (%) The probabilities (in percentage) of choosing the comparison figure having the same configuration as the standard figure. That is, the ratio between the number of trials in which participants chose the comparison figure as having the same configuration as the standard figure, and the total number of trials. 2 weeks.
Primary Performance in Experiment 2: Response Time (milliseconds) Response Time in milliseconds; will be measured from stimulus onset on screen until prticipant's response. 2 weeks.
Primary Performance in Experiment 2: Error Rate (%) Percentage of Errors; The ratio between number of errors and the total number of responses. 2 weeks.
See also
  Status Clinical Trial Phase
Recruiting NCT05039489 - A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia N/A
Completed NCT05111548 - Brain Stimulation and Cognitive Training - Efficacy N/A
Completed NCT05321602 - Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder Phase 1
Completed NCT04503954 - Efficacy of Chronic Disease Self-management Program in People With Schizophrenia N/A
Completed NCT02831231 - Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium Phase 1
Completed NCT05517460 - The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center N/A
Completed NCT03652974 - Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy Phase 4
Recruiting NCT04012684 - rTMS on Mismatch Negativity of Schizophrenia N/A
Recruiting NCT04481217 - Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia N/A
Completed NCT00212784 - Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935) Phase 3
Completed NCT04092686 - A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia Phase 3
Completed NCT01914393 - Pediatric Open-Label Extension Study Phase 3
Recruiting NCT03790345 - Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics Phase 2/Phase 3
Recruiting NCT05956327 - Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training N/A
Terminated NCT03261817 - A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders N/A
Terminated NCT03209778 - Involuntary Memories Investigation in Schizophrenia N/A
Completed NCT02905604 - Magnetic Stimulation of the Brain in Schizophrenia or Depression N/A
Recruiting NCT05542212 - Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia N/A
Completed NCT04411979 - Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia N/A
Terminated NCT03220438 - TMS Enhancement of Visual Plasticity in Schizophrenia N/A